papaveretum
CLINICAL USE
Opiate analgesia
DOSE IN NORMAL RENAL FUNCTION
SC/IM: 0.5–1 mL every 4 hoursIV: 25–50% of dose
PHARMACOKINETICS
Papaverine Morphine Codeine Molecular weight (daltons)375.8375.8371.9% Protein binding9020–357% Excreted unchanged in urine<110<5Volume of distribution (L/kg)0.99–1.52 3–53–4half-life – normal/ESRD (hrs)1.2–2.2/– 2–3/ Un-changed2.5–4/–
DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
20 to 50     : Dose as in normal renal function 10 to 20     : 0.4–0.75 mL every 6–8 hours <10           : 0.25–0.5 mL every 6–8 hours. Avoid if possible DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Unlikely to be dialysed. Dose as in GFR <10 mL/min HD                     :Unlikely to be dialysed. Dose as in GFR <10 mL/min HDF/high flux   :Unlikely to be dialysed. Dose as in GFR <10 mL/min CAV/VVHD      :Unknown dialysability. Dose as in GFR 10 to 20 mL/min IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugsAnti-arrhythmics: delayed absorption of mexiletineAntidepressants: possible CNS excitation or depression with MAOIs – avoid concomitant use; possible CNS excitation or depression with moclobemide; increased sedative effects with tricyclicsAntivirals: concentration possibly increased with ritonavirSodium oxybate: enhanced effect of sodium oxybate – avoid concomitant use ADMINISTRATION
Reconstition
– Route
SC, IM, IV Rate of Administration
IV bolus or continuous infusion (1 mg/mL) Comments
– OTHER INFORMATION
As with all opiates, use with extreme caution in patients with impaired renal functionMay cause excessive sedation and respiratory depressionPapaveretum 15.4 mg =1 mL ≡ 10 mg morphine.
See how to identify renal failure stages according to GFR calculation
See how to diagnose irreversible renal disease
Home